Dissociative Disorders
6 cases on depersonalization/derealization disorder, dissociative identity disorder, and dissociative symptom pharmacology — choose a case below to open its full multi-voice debate.
A 27-year-old woman with four years of persistent depersonalization has tried an SSRI and eighteen months of therapy without resolving the core symptom. The team disagrees about whether a thin but real evidence trail on naltrexone is enough to justify a trial now, rather than later.
A married chemistry teacher with three years of stable anxiety control still carries the depersonalization that triggered it. The disagreement isn't whether lamotrigine augmentation could help — it's whether a slow, rash-risk titration is worth it for someone already functioning well.
A woman with dissociative identity disorder isn't responding to an adequate sertraline trial for a new depressive episode. The team is divided on what "not responding" can even mean when a single symptom score may not reflect her whole system.
A truck driver's situational anxiety prescription has become a near-daily habit — and a new symptom, dissociation, that looks like it might be coming from the very drug meant to treat his anxiety. The disagreement is over how carefully, not whether, to take it away.
A nurse with six years of depersonalization has been offered fluoxetine on general principle. The real evidence for that specific drug in that specific condition is a negative randomized trial — and the team has to decide what that negative result should actually mean for her.
A family wants a sodium amobarbital interview to help a husband recover memories lost during a dissociative fugue. The team's disagreement isn't about the family's hope — it's about whether any version of this technique still has a legitimate job left to do.